{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
adenosine
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Adenosine 2'-monophosphate (2’-AMP) is adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'- position. Exogenous 2’-AMP is rapidly converted to adenosine in vitro and in vivo. In vitro 2’-AMP alter vascular smooth muscle cell, endothelial cell, and epithelial cell proliferation via adenosine receptors activation. In vitro 2’-AMP dose-dependently and profoundly reduce mean arterial blood pressure, heart rate, total peripheral (TPR), mesenteric vascular (MVR) resistances with efficacies and potencies equal to or greater than those for adenosine. Adenosine 2'-monophosphate has been used in the synthesis of a novel photoaffinity label for the coenzyme site of porcine NADP-specific isocitrate dehydrogenase. Adenosine 2'-monophosphate also can be used as a tool for studying adenosine-based cell regulation.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
I-AB-MECA is iodinated form of parent compound - adenosine derivative, 4-aminobenzyl-5'-N-methylcarboxamidoadenosine (AB-MECA). AB-MECA i a potent agonist of adenosine A3 receptor agonist. 125I-labeled AB-MECA is widely used in in vitro pharmacological studies of adenosine A3 receptor as a refernece ligand. In addition I-AB-MECA is usefull in vitro autoradiography to map adenosine A3 receptor distribution tissues. I-AB-MECA bound to the rat adenosine A1 receptor and canine adenosine A2a receptor.
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
LY294002 is a morpholine-containing chemical compound that is a potent inhibitor of numerous proteins, and a strong inhibitor of phosphoinositide 3-kinases (PI3Ks). It was previously under active development by Eli Lily and was tested in a number of clinical cancer trials including neuroblastomas and head and neck cancer. However, commercialization efforts have been discontinued, and LY294002 is now predominantly used as a research tool.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
SCH-58261 is an antagonist of the Adenosine A2A receptor with a Kd of 2.3 nM. It was initially identified and developed by Schering-Plough as a potential treatment for neurological conditions such as Parkinson's Disease and Depression. However, the compound suffered from poor solubility and is not active when orally dosed. SCH-58261 became the scaffold for the development of Preladenant (SCH 412348), which did progress to Phase III clinical trials before being discontinued. There has also been an investigation of SCH-58261 as a treatment of hypotension in rat models.
